| Attribute |
Value |
| 52 Week Change |
1.4916482 |
| Address1 |
555 Heritage Drive |
| Address2 |
Suite 200 |
| All Time High |
326.63 |
| All Time Low |
4.11728 |
| Ask |
395.73 |
| Ask Size |
2 |
| Audit Risk |
8 |
| Average Analyst Rating |
1.2 - Strong Buy |
| Average Daily Volume10 Day |
536,180 |
| Average Daily Volume3 Month |
334,359 |
| Average Volume |
334,359 |
| Average Volume10Days |
536,180 |
| Beta |
0.976 |
| Bid |
223.25 |
| Bid Size |
2 |
| Board Risk |
4 |
| Book Value |
49.794 |
| City |
Jupiter |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
3 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
309.25 |
| Current Ratio |
21.281 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
316.42 |
| Day Low |
304.77 |
| Debt To Equity |
45.319 |
| Earnings Call Timestamp End |
1,778,157,000 |
| Earnings Call Timestamp Start |
1,778,157,000 |
| Earnings Timestamp |
1,778,157,000 |
| Earnings Timestamp End |
1,786,019,400 |
| Earnings Timestamp Start |
1,786,019,400 |
| Ebitda |
134,447,008 |
| Ebitda Margins |
0.48983002 |
| Enterprise To Ebitda |
43.662 |
| Enterprise To Revenue |
21.387 |
| Enterprise Value |
5,870,269,952 |
| Eps Current Year |
9.15714 |
| Eps Forward |
11.48167 |
| Eps Trailing Twelve Months |
7.68 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,278,028,800 |
| Exchange |
NGM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
253.248 |
| Fifty Day Average Change |
56.002 |
| Fifty Day Average Change Percent |
0.221135 |
| Fifty Two Week Change Percent |
149.16483 |
| Fifty Two Week High |
326.63 |
| Fifty Two Week High Change |
-17.380005 |
| Fifty Two Week High Change Percent |
-0.05321007 |
| Fifty Two Week Low |
120.68 |
| Fifty Two Week Low Change |
188.57 |
| Fifty Two Week Low Change Percent |
1.5625622 |
| Fifty Two Week Range |
120.68 - 326.63 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
722,097,000,000 |
| Float Shares |
19,528,010 |
| Forward Eps |
11.48167 |
| Forward P E |
26.934235 |
| Free Cashflow |
142,107,376 |
| Full Exchange Name |
NasdaqGM |
| Full Time Employees |
47 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,782,864,000 |
| Gross Margins |
0.83161 |
| Gross Profits |
228,258,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.023670001 |
| Held Percent Institutions |
1.07138 |
| Implied Shares Outstanding |
20,041,061 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ir Website |
http://investor.ligand.com/Investors/Investor-Overview/default.aspx |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Dividend Date |
1,175,558,400 |
| Last Dividend Value |
9.357455 |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,667,347,200 |
| Last Split Factor |
1,603:1000 |
| Long Business Summary |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida. |
| Long Name |
Ligand Pharmaceuticals Incorporated |
| Market |
us_market |
| Market Cap |
6,197,698,048 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_30820 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
153,559,008 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
6,337,785,130 |
| Number Of Analyst Opinions |
10 |
| Open |
322.23 |
| Operating Cashflow |
123,495,000 |
| Operating Margins |
0.33580002 |
| Overall Risk |
4 |
| Payout Ratio |
0.0 |
| Peg Ratio |
1.53 |
| Phone |
858 550 7500 |
| Previous Close |
316.24 |
| Price Eps Current Year |
33.77146 |
| Price Hint |
2 |
| Price To Book |
6.210588 |
| Price To Sales Trailing12 Months |
22.580109 |
| Profit Margins |
0.55946 |
| Quick Ratio |
20.812 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
strong_buy |
| Recommendation Mean |
1.22222 |
| Region |
US |
| Regular Market Change |
-6.98999 |
| Regular Market Change Percent |
-2.21034 |
| Regular Market Day High |
316.42 |
| Regular Market Day Low |
304.77 |
| Regular Market Day Range |
304.77 - 316.42 |
| Regular Market Open |
322.23 |
| Regular Market Previous Close |
316.24 |
| Regular Market Price |
309.25 |
| Regular Market Time |
1,783,972,801 |
| Regular Market Volume |
245,695 |
| Return On Assets |
0.051909998 |
| Return On Equity |
0.1713 |
| Revenue Growth |
0.141 |
| Revenue Per Share |
14.068 |
| Sand P52 Week Change |
0.20847368 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
5 |
| Shares Outstanding |
20,041,061 |
| Shares Percent Shares Out |
0.105900005 |
| Shares Short |
2,121,617 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
1,638,411 |
| Short Name |
Ligand Pharmaceuticals Incorpor |
| Short Percent Of Float |
0.1268 |
| Short Ratio |
4.25 |
| Source Interval |
15 |
| State |
FL |
| Symbol |
LGND |
| Target High Price |
388.0 |
| Target Low Price |
247.0 |
| Target Mean Price |
297.5 |
| Target Median Price |
285.0 |
| Total Cash |
779,404,992 |
| Total Cash Per Share |
38.89 |
| Total Debt |
451,976,992 |
| Total Revenue |
274,476,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
7.68 |
| Trailing P E |
40.26693 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
211.13216 |
| Two Hundred Day Average Change |
98.11784 |
| Two Hundred Day Average Change Percent |
0.4647224 |
| Type Disp |
Equity |
| Volume |
245,695 |
| Website |
https://www.ligand.com |
| Zip |
33,458 |